Gossamer Bio, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| GOSS | GTBP | RNTX | GANX | PASG | BDTX | |
|---|---|---|---|---|---|---|
| Market cap | 56.76M | 12.27M | 67.71M | 68.52M | 14.64M | 101.42M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.6 | -0.6 | — | -2.3 | -0.4 | -1.8 |
| Price/book | -0.6 | 3.4 | 6.6 | 6.0 | 3.3 | 1.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −95.23% | −63.79% | −39.85% | −13.68% | −57.54% | −51.84% |
| Today | −0.32% | +1.80% | −1.15% | −4.27% | +23.31% | −3.28% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All GOSS news ›Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash?
Gossamer Bio Inc. (GOSS) on Monday released topline findings from its late-stage PROSERA trial evaluating seralutinib in patients with pulmonary arterial hypertension (PAH), offering a mixed picture as the company weighs its regulatory…
Gossamer Bio: D. E. Shaw reports votes on 369,459 shares
Sold shares count toward October meeting voting power at Gossamer Bio (GOSS). Stock Titan - [SCHEDULE 13D/A] Gossamer Bio, Inc. Amended Major Shareholder Report Gossamer Bio: D. E. Shaw reports votes on 369,459 shares Reported voting power…
Gossamer Bio grants director option on 10,000 shares
Gossamer Bio (GOSS) is a late-stage clinical biopharmaceutical company developing inhaled seralutinib for pulmonary arterial hypertension and PH-ILD. - [Form 4] Gossamer Bio, Inc. Insider Trading Activity Gossamer Bio grants director…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
stocktitan.net2
-
stocktwits.com1
-
tradingview.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 4 articles, not a forecast.